RAC1 exon 3A (activated by ESRP2) falls into the ‘grey’ area when comparing inclusion in normal versus prostate cancer, but more detailed analysis show that this exon is highly included in higher Gleason grades of prostate cancer, again to produce the RAC1 splicing isoform associated with a decreased time to biochemical recurrence (Figure 5—figure supplement 2C). This evidence concerns the gene ESRP2 and prostate cancer.